Litchfield Caroline's most recent trade in Merck & Co Inc was a trade of 46,566 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 46,566 | 46,566 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 15,908 | 15,908 | - | - | Restricted Stock Unit | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 110.03 per share. | 29 Apr 2026 | 3,935 | 94,238 (0%) | 0% | 110.0 | 432,968 | Common Stock |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2026 | 3,935 | 7,870 | - | - | Restricted Stock Unit | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.03 per share. | 29 Apr 2026 | 1,938 | 92,300 (0%) | 0% | 110.0 | 213,238 | Common Stock |
| Verizon Communincations | Caroline A. Litchfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2026 | 5,062 | 11,402 | - | - | Phantom Stock | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2026 | 41,997 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.06 per share. | 04 Feb 2026 | 41,997 | 132,189 (0%) | 0% | 53.1 | 2,228,361 | Common Stock |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Sale of securities on an exchange or to another person at price $ 119.61 per share. | 04 Feb 2026 | 41,997 | 90,192 (0%) | 0% | 119.6 | 5,023,312 | Common Stock |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 107.40 per share. | 26 Jan 2026 | 15,852 | 90,192 (0%) | 0% | 107.4 | 1,702,505 | Common Stock |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 53,735 | 53,735 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2025 | 11,805 | 11,805 | - | - | Restricted Stock Unit | |
| Verizon Communincations | Caroline A. Litchfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 4,748 | 5,948 | - | - | Phantom Stock | |
| Merck & Company | Caroline A. Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 97.94 per share. | 27 Jan 2025 | 23,432 | 74,340 (0%) | 0% | 97.9 | 2,294,930 | Common Stock |
| Verizon Communincations | Caroline A. Litchfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 1,161 | 1,161 | - | - | Phantom Stock | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 49,805 | 49,805 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Litchfield Caroline | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.08 per share. | 14 Feb 2024 | 38,291 | 89,199 (0%) | 0% | 58.1 | 2,223,941 | Common Stock |
| Merck & Company | Litchfield Caroline | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 38,291 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Sale of securities on an exchange or to another person at price $ 125.50 per share. | 14 Feb 2024 | 38,291 | 50,908 (0%) | 0% | 125.5 | 4,805,521 | Common Stock |
| Merck & Company | Litchfield Caroline | EVP & CFO | Grant, award, or other acquisition of securities at price $ 119.43 per share. | 22 Jan 2024 | 19,208 | 50,908 (0%) | 0% | 119.4 | 2,294,011 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 58,783 | 58,783 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 866 | 0 | - | - | Restricted Stock Unit | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 115.47 per share. | 01 May 2023 | 866 | 32,118 (0%) | 0% | 115.5 | 99,997 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.47 per share. | 01 May 2023 | 427 | 31,691 (0%) | 0% | 115.5 | 49,306 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 109.88 per share. | 23 Jan 2023 | 2,656 | 30,186 (0%) | 0% | 109.9 | 291,841 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2022 | 53,398 | 53,398 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.65 per share. | 03 May 2022 | 773 | 27,799 (0%) | 0% | 87.6 | 67,753 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 773 | 0 | - | - | Restricted Stock Unit | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.65 per share. | 03 May 2022 | 373 | 27,426 (0%) | 0% | 87.6 | 32,693 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.69 per share. | 01 May 2022 | 866 | 27,453 (0%) | 0% | 88.7 | 76,806 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2022 | 866 | 866 | - | - | Restricted Stock Unit | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.69 per share. | 01 May 2022 | 427 | 27,026 (0%) | 0% | 88.7 | 37,871 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Grant, award, or other acquisition of securities at price $ 73.51 per share. | 24 Feb 2022 | 2,429 | 26,555 (0%) | 0% | 73.5 | 178,556 | Common Stock |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 22,683 | 0 | - | - | Stock Option (Right to Buy) | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 22,683 | 42,448 (0%) | 0% | 0 | Common Stock | |
| Merck & Company | Caroline Litchfield | EVP & CFO | Sale of securities on an exchange or to another person at price $ 91.00 per share. | 04 Nov 2021 | 18,335 | 24,113 (0%) | 0% | 91.0 | 1,668,503 | Common Stock |